[1] Ravikumar G, Ananthamurthy A. Cyclin D1 expression in ductal carcinoma of the breast and its correlation with other prognostic parameters[J]. J Cancer Res Ther, 2014,10(3)∶671-675 [2] Xavier FC, Rodini CO, Paiva KB, et al. ORAOV1 is amplified in oral squamous cell carcinoma[J]. J Oral Pathol Med, 2012,41(1)∶54-60 [3] Zhao H, Zhang H, Du Y, et al. Prognostic significance of BRCA1, ERCC1, RRM1, and RRM2 in patients with advanced non-small cell lung cancer receiving chemotherapy[J]. Tumour Biol, 2014 [4] 安虹,王亚利,郝小静,等.舌鳞癌组织中Cyclin D1的表达与临床病理相关性[J]. 第四军医大学学报,2004,(02)∶179-181 [5] 王恒琨,张文峰,陈新明,等.舌鳞癌组织中Cyclin D1、P27及c-erbB-2的表达及意义[J]. 武汉大学学报(医学版),2006,(02)∶214-216 [6] Xia J, Chen Q, Li B, et al. Amplifications of TAOS1 and EMS1 genes in oral carcinogenesis: association with clinicopathological features[J]. Oral Oncol, 2007, 43(5)∶508-514 [7] Jiang L, Zeng X, Yang H, et al. Oral cancer overexpressed 1 (ORAOV1): a regulator for the cell growth and tumor angiogenesis in oral squamous cell carcinoma[J]. Int J Cancer, 2008, 123(8)∶1779-1786 [8] Yang ZH, Dai Q, Kong XL, et al. Association of ERCC1 polymorphisms and susceptibility to nasopharyngeal carcinoma[J]. Mol Carcinog, 2009, 48(3)∶196-201 [9] Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer[J]. Chest, 2005, 127(3)∶978-983 [10] Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy[J]. N Engl J Med Overseas Ed, 2006, 355(10)∶983-991 |